Jane Street’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $972K | Sell |
17,200
-18,100
| -51% | -$1.06M | ﹤0.01% | 6558 |
|
|
2025
Q4 | $2.1M | Buy |
35,300
+900
| +3% | +$49K | ﹤0.01% | 4728 |
|
|
2025
Q3 | $1.86M | Buy |
34,400
+3,400
| +11% | +$194K | ﹤0.01% | 5070 |
|
|
2025
Q2 | $1.7M | Sell |
31,000
-6,900
| -18% | -$406K | ﹤0.01% | 4688 |
|
|
2025
Q1 | $2.68M | Sell |
37,900
-23,700
| -38% | -$1.59M | ﹤0.01% | 3891 |
|
|
2024
Q4 | $4.05M | Sell |
61,600
-12,500
| -17% | -$837K | ﹤0.01% | 2965 |
|
|
2024
Q3 | $5.21M | Sell |
74,100
-471,500
| -86% | -$39.4M | ﹤0.01% | 2804 |
|
|
2024
Q2 | $44.9M | Sell |
545,600
-23,900
| -4% | -$1.99M | 0.01% | 750 |
|
|
2024
Q1 | $49.7M | Buy |
569,500
+528,000
| +1,272% | +$47.3M | 0.01% | 635 |
|
|
2023
Q4 | $4M | Sell |
41,500
-73,100
| -64% | -$6.47M | ﹤0.01% | 3182 |
|
|
2023
Q3 | $10.1M | Sell |
114,600
-360,100
| -76% | -$32M | ﹤0.01% | 1754 |
|
|
2023
Q2 | $41.1M | Buy |
474,700
+416,500
| +716% | +$39.2M | 0.01% | 706 |
|
|
2023
Q1 | $5.66M | Sell |
58,200
-81,200
| -58% | -$8.42M | ﹤0.01% | 2280 |
|
|
2022
Q4 | $14.4M | Buy |
139,400
+18,300
| +15% | +$1.72M | 0.01% | 1270 |
|
|
2022
Q3 | $10.3M | Sell |
121,100
-31,100
| -20% | -$2.77M | ﹤0.01% | 1668 |
|
|
2022
Q2 | $12.6M | Buy |
152,200
+5,800
| +4% | +$462K | 0.01% | 1502 |
|
|
2022
Q1 | $11.3M | Sell |
146,400
-10,200
| -7% | -$853K | ﹤0.01% | 1841 |
|
|
2021
Q4 | $13.8M | Buy |
156,600
+83,100
| +113% | +$6.86M | ﹤0.01% | 1515 |
|
|
2021
Q3 | $5.68M | Sell |
73,500
-29,100
| -28% | -$2.3M | ﹤0.01% | 2535 |
|
|
2021
Q2 | $8.56M | Sell |
102,600
-36,500
| -26% | -$2.89M | ﹤0.01% | 1890 |
|
|
2021
Q1 | $10.5M | Sell |
139,100
-113,000
| -45% | -$9.23M | 0.01% | 1500 |
|
|
2020
Q4 | $22.1M | Buy |
252,100
+27,500
| +12% | +$2.18M | 0.01% | 811 |
|
|
2020
Q3 | $17.1M | Buy |
224,600
+17,900
| +9% | +$1.81M | 0.01% | 858 |
|
|
2020
Q2 | $25.5M | Buy |
206,700
+157,100
| +317% | +$15.6M | 0.02% | 634 |
|
|
2020
Q1 | $4.19M | Sell |
49,600
-53,900
| -52% | -$4.64M | ﹤0.01% | 1320 |
|
|
2019
Q4 | $8.75M | Buy |
103,500
+97,400
| +1,597% | +$7.36M | 0.01% | 720 |
|
|
2019
Q3 | $411K | Sell |
6,100
-46,300
| -88% | -$3.57M | ﹤0.01% | 3782 |
|
|
2019
Q2 | $4.49M | Buy |
52,400
+42,700
| +440% | +$3.65M | 0.01% | 1128 |
|
|
2019
Q1 | $862K | Sell |
9,700
-13,000
| -57% | -$1.2M | ﹤0.01% | 2990 |
|
|
2018
Q4 | $1.93M | Buy |
22,700
+7,100
| +46% | +$675K | ﹤0.01% | 1773 |
|
|
2018
Q3 | $1.51M | Sell |
15,600
-7,400
| -32% | -$739K | ﹤0.01% | 2221 |
|
|
2018
Q2 | $2.17M | Buy |
23,000
+9,500
| +70% | +$832K | 0.01% | 1843 |
|
|
2018
Q1 | $1.09M | Sell |
13,500
-30,100
| -69% | -$2.58M | ﹤0.01% | 2555 |
|
|
2017
Q4 | $3.89M | Buy |
43,600
+41,300
| +1,796% | +$3.59M | 0.01% | 1038 |
|
|
2017
Q3 | $214K | Sell |
2,300
-2,300
| -50% | -$203K | ﹤0.01% | 4066 |
|
|
2017
Q2 | $418K | Buy |
+4,600
| New | +$418K | ﹤0.01% | 3242 |
|
|
2017
Q1 | – | Sell |
-26,400
| Closed | -$2.19M | – | 4135 |
|
|
2016
Q4 | $2.19M | Buy |
26,400
+15,600
| +144% | +$1.34M | 0.01% | 1236 |
|
|
2016
Q3 | $999K | Buy |
10,800
+8,000
| +286% | +$753K | ﹤0.01% | 1962 |
|
|
2016
Q2 | $218K | Sell |
2,800
-33,500
| -92% | -$2.85M | ﹤0.01% | 3647 |
|
|
2016
Q1 | $2.99M | Buy |
36,300
+26,500
| +270% | +$2.16M | 0.02% | 874 |
|
|
2015
Q4 | $1.03M | Buy |
9,800
+7,300
| +292% | +$762K | 0.01% | 1712 |
|
|
2015
Q3 | $263K | Buy |
+2,500
| New | +$334K | ﹤0.01% | 2922 |
|
Other funds holding BMRN
VCM
VPM
Jane Street's BMRN Position: Q1 2026 in Review
Jane Street reduced its BioMarin Pharmaceuticals (BMRN) stake by 97% in Q1 2026, selling an estimated $11.4M and leaving 5,133 shares worth $290K. The position accounts for ﹤0.01% of the portfolio, ranked #9306.
Jane Street first reported a position in BMRN in Q2 2013 and has held it in 48 quarters since. The position peaked at $25.3M in Q1 2024. 555 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Jane Street held 5,133 shares of BioMarin Pharmaceuticals worth $290K as of Q1 2026.
- Jane Street sold 195,833 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $11.4M.
- BioMarin Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #9306 holding.
- Jane Street first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 48 quarters since.
- Jane Street's BioMarin Pharmaceuticals position peaked at $25.3M in Q1 2024.
- 555 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.